RemeGen Co. Ltd
RemeGen Co., Ltd., a biopharmaceutical company, discovers, develops, produces, and commercializes biological drugs for the treatment of autoimmune, oncology, and ophthalmic diseases in Mainland China and the United States. The company offers Telitacicept (RC18) for the treatment of systemic lupus erythematosus (SLE) autoimmune disease; and Disitamab Vedotin (RC48), an antibody drug conjugate for … Read more
RemeGen Co. Ltd (REGMF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.198x
Based on the latest financial reports, RemeGen Co. Ltd (REGMF) has a cash flow conversion efficiency ratio of 0.198x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($460.18 Million) by net assets ($2.32 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
RemeGen Co. Ltd - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how RemeGen Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
RemeGen Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of RemeGen Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shandong Weida Machinery Co Ltd
SHE:002026
|
0.025x |
|
Daheng New Epoch Technology Inc
SHG:600288
|
0.026x |
|
Dashang Co Ltd
SHG:600694
|
0.006x |
|
Eco World Develop Group
KLSE:8206
|
0.031x |
|
Kaili Catalyst & New Materials Co. Ltd. A
SHG:688269
|
0.009x |
|
Shenzhen Jinjia Color Printing Group Co Ltd
SHE:002191
|
0.046x |
|
YG Entertainment Inc
KQ:122870
|
0.041x |
|
FORUM ENERGY TECH. DL-01
F:1FE1
|
N/A |
Annual Cash Flow Conversion Efficiency for RemeGen Co. Ltd (2018–2024)
The table below shows the annual cash flow conversion efficiency of RemeGen Co. Ltd from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.99 Billion | $-1.18 Billion | -0.592x | -35.58% |
| 2023-12-31 | $3.44 Billion | $-1.50 Billion | -0.437x | -72.20% |
| 2022-12-31 | $4.98 Billion | $-1.26 Billion | -0.254x | -431.71% |
| 2021-12-31 | $3.45 Billion | $263.63 Million | 0.076x | +141.66% |
| 2020-12-31 | $3.59 Billion | $-660.08 Million | -0.184x | -115.07% |
| 2019-12-31 | $-231.97 Million | $-282.75 Million | 1.219x | +374.29% |
| 2018-12-31 | $-498.18 Million | $-128.03 Million | 0.257x | -- |